Lets Clear things up here!!LSALT Peptide (LSALT and “Metablok”) will enter the Canadian Treatments for COVID-19 (CATCO) human trial, a multi-centre adaptive, randomized, open-label, controlled study being conducted in sixty-five hospitals across Canada, in conjunction with the World Health Organization’s (WHO) SOLIDARITY trial, in collaboration with countries around the world and with support from the Canadian Institutes of Health Research (CIHR)-funded Canadian Network of COVID-19 Clinical Trials Networks. LSALT will be evaluated in the Canadian trial.
CATCO Has Accepted ARCH into the Trial
CATCO is a network of 65 hospitals across Canada
CATCO is in conjunction with the World Health Organization’s (WHO) SOLIDARITY trial
The Phase III Trial is Canadian Institutes of Health Research (CIHR)-funded
An Average Phase III trial costs 30-50 million
CATCO Third Party Verified the DATA
Publication is pending for the Science
THE DRUG HAS BEEN MADE!